Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer

NCT07278336 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07278336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07278336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Recruiting
Start date
November 27, 2025
Completion date
January 31, 2029
Enrollment
285 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer